Cornerstone Investment Partners LLC Purchases New Position in Roche Holdings AG Basel ADR (RHHBY)
Cornerstone Investment Partners LLC purchased a new position in shares of Roche Holdings AG Basel ADR (OTCMKTS:RHHBY) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 6,834 shares of the company’s stock, valued at approximately $206,000.
Other large investors have also recently added to or reduced their stakes in the company. Gardiner Nancy B purchased a new position in Roche Holdings AG Basel during the 3rd quarter worth approximately $454,000. Chartwell Investment Partners LLC purchased a new position in shares of Roche Holdings AG Basel in the 2nd quarter valued at approximately $743,000. Chickasaw Capital Management LLC grew its stake in shares of Roche Holdings AG Basel by 5.0% in the 2nd quarter. Chickasaw Capital Management LLC now owns 42,000 shares of the company’s stock valued at $1,166,000 after purchasing an additional 2,000 shares during the last quarter. Jolley Asset Management LLC purchased a new position in shares of Roche Holdings AG Basel in the 2nd quarter valued at approximately $1,576,000. Finally, Meritage Portfolio Management purchased a new position in shares of Roche Holdings AG Basel in the 2nd quarter valued at approximately $3,073,000. Hedge funds and other institutional investors own 0.57% of the company’s stock.
Shares of Roche Holdings AG Basel stock traded up $0.73 during trading on Friday, reaching $30.57. The company’s stock had a trading volume of 914,215 shares, compared to its average volume of 903,955. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.28 and a quick ratio of 0.97. Roche Holdings AG Basel ADR has a 12-month low of $26.30 and a 12-month high of $32.42. The company has a market cap of $203.10 billion, a PE ratio of 15.68, a price-to-earnings-growth ratio of 1.88 and a beta of 0.62.
About Roche Holdings AG Basel
Roche Holding AG diagnostics and pharmaceuticals businesses in Switzerland, Germany, and rest of Europe. It offers pharmaceutical products for anaemia, anticoagulation therapy, bone, cancer, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, HPV, infectious diseases, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid disorders, liver, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and West Nile virus diseases.
Featured Story: Google Finance
Want to see what other hedge funds are holding RHHBY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Roche Holdings AG Basel ADR (OTCMKTS:RHHBY).
Receive News & Ratings for Roche Holdings AG Basel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holdings AG Basel and related companies with MarketBeat.com's FREE daily email newsletter.